Published in
Taylor and Francis Group, Hematology, 4(23), p. 212-220, 2017
DOI: 10.1080/10245332.2017.1385193
Links
Tools
Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature
Journal article published in 2017 by
Seniz Ongoren,
Ahmet Emre Eskazan 
,
Veysel Suzan,
Sercan Savci,
Isil Erdogan Ozunal,
Selin Berk,
Fevzi Fırat Yalniz ,
Tugrul Elverdi,
Ayse Salihoglu,
Yucel Erbilgin,
Sibel Aylin Iseri,
Muhlis Cem Ar,
Zafer Baslar,
Yildiz Aydin,
Nukhet Tuzuner
and other authors.
,
Veysel Suzan,
Sercan Savci,
Isil Erdogan Ozunal,
Selin Berk,
Fevzi Fırat Yalniz ,
Tugrul Elverdi,
Ayse Salihoglu,
Yucel Erbilgin,
Sibel Aylin Iseri,
Muhlis Cem Ar,
Zafer Baslar,
Yildiz Aydin,
Nukhet Tuzuner
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 